Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects (Q35035145)

5 August 2017

1 reference

title

Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects (English)

1 reference

5 August 2017

0 references

Halbreich U

1

1 reference

5 August 2017

Kinon BJ

series ordinal

2

1 reference

5 August 2017

Gilmore JA

series ordinal

3

1 reference

5 August 2017

Kahn LS

series ordinal

4

1 reference

5 August 2017

1 January 2003

1 reference

5 August 2017

15

1 reference

inferred from page(s)

published in

Psychoneuroendocrinology

1 reference

5 August 2017

28 Suppl 1

1 reference

5 August 2017

53-67

1 reference

Osteoporosis and schizophrenia: can we limit known risk factors?

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Human breast cancer: concerted role of diet, prolactin and adrenal C19-delta 5-steroids in tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Relative effects of prolactin excess and estrogen deficiency on bone in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Prolactin changes in major depressive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

The neuroendocrine response to fenfluramine in depressives and normal controls

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Management of depression in medical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Psychosomatic aspects of hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Prevalence and presentation of hyperprolactinaemia in patients with "functionless" pituitary tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Increase in serum prolactin by exogenous and endogenous opiates: evidence for antidopamine and antipsychotic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Quetiapine fumarate (Seroquel): a new atypical antipsychotic.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Prolactin Responses to Neuroleptics in Normal and Schizophrenic Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

The prolactin response to intravenous dextroamphetamine in normal young men and postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Decreased bone mineral density in medicated psychiatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Are chronic psychiatric patients at increased risk for developing breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Pituitary hormone release in response to food ingestion: evidence for neuroendocrine signals from gut to brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Cancer mortality among patients in New York mental hospitals.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Abnormal prolactin response to haloperidol challenge in men with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Hyperprolactinemia, distress, and hostility.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Breast cancer: magnitude of the problem and descriptive epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Decreased bone density in hyperprolactinemic women

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Physical comorbidity and polypharmacy in older psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Lithium discontinuation, serum cortisol, and 5-HTP

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Diurnal variation of prolactin secretion differentiates pituitary tumors from the primary empty sella syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Ovarian steroids and the brain: implications for cognition and aging

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Bone mineral density in women with depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Plasma prolactin and testosterone during penfluridol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Prolactin and antipsychotic medications: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Charge Properties of Human Pituitapy and Amniotic Fluid Prolactins

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Risk factors for cardiovascular disease in women: assessment and management

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Circulating nitric oxide levels in galactorrheic, hyperprolactinemic, amenorrheic women

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Mechanisms that subserve estradiol's induction of increased prolactin concentrations: evidence of amplitude modulation of spontaneous prolactin secretory bursts

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Clinical and neuroendocrine effects of zotepine--a new neuroleptic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Sexual dysfunction associated with hyperprolactinemia in males and females undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Galactorrhea: subjective response by schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900112-9

7 January 2021

10.1016/S0306-4530(02)00112-9

Identifiers

DOI

1 reference

5 August 2017

1 reference